An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone (e-STAR)
Electronic Schizophrenia Treatment Adherence Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient who started long-acting injectable risperidone treatment after agreement between doctor and patient
- Ambulatory patient or not chronically full-time hospitalized patient. Full-time hospitalization at the moment of inclusion for maximal 6 months
- The treatment and treated indication according to local label
- Patient had given informed consent in agreement with local legislation
Exclusion Criteria:
- Patient participating in another medication related study, chronically full-time hospitalized patient, who according to the treating physician had no perspective of being discharged within the planned observation period
- Patient suffering from treatment resistant schizophrenia
- Pregnant or breastfeeding females or females with planned pregnancy within two years
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with Schizophrenia
Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
|
Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in total length of hospitalization from retrospective to prospective period
Time Frame: 48 months
|
Start date, end date of full-time or partial hospitalization will be recorded both in retrospective and prospective study period.
|
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline to 24 months in Clinical Global Impression (CGI) Scale scores
Time Frame: Baseline, (just before the first injection of long-acting injectable risperidone) to 24 months
|
Patients are rated for overall severity of schizophrenia disorder using the CGI scale (7 point scale) in which 1 = Not Ill and 7 = Extremely Severe.
|
Baseline, (just before the first injection of long-acting injectable risperidone) to 24 months
|
|
Change from baseline to 24 months in Global Assessment of Functioning (GAF) scores
Time Frame: Baseline to 24 months
|
This GAF scale rates the functioning of the patient on a scale of 1 - 100 where "1 - 10" is "Persistant danger of severely hurting self or others (eg, recurrent violence) OR persistant inability to maintain personal hygiene OR serious suicidal act with clear expectations of death" and "91- 100" is "Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his of her positive qualities.
No symptoms"
|
Baseline to 24 months
|
|
Change from baseline to 24 months in clinical deterioration
Time Frame: Baseline, in 3-monthly intervals (± 2 weeks) for 24 months and Last visit
|
Clinical deterioration is assessed by evaluating presence or absence of deliberate self injury, suicidal or homicidal ideation, violent behaviour, and increased need in levels of care and increase in CGI by 2 points or more.
The maintenance of treatment effect is documented by the time to significant deterioration of the psychotic condition.
If signs of significant deterioration occurred more than once within each 3 monthly interval, this is recorded.
|
Baseline, in 3-monthly intervals (± 2 weeks) for 24 months and Last visit
|
|
Change from baseline to 24 months in assessment of remission
Time Frame: Baseline to 24 months
|
Clinical status will be assessed by presence or absence of the following core symptoms: delusions, conceptual disorganization, hallucinatory behavior, mannerisms and posturing, unusual thought content, blunted affect, passive/apathetic social withdrawal, lack of spontaneity and flow of conversation.
Score will be given for each symptom as follows: Score 1: Absent, Minimal, Mild; Score 2: Moderate, Moderately severe, Severe, Extreme.
Symptomatic remission is defined as a clinical status where for each and every of the symptoms prespecified, a score of 1 can be given for duration of 6 months.
|
Baseline to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen-Cilag N.V./S.A., Belgium Clinical Trial, Janssen Cilag N.V./S.A.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR003886
- RISSCH4002 (Other Identifier: Janssen Cilag N.V./S.A., Belgium)
- 2004-002448-93 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.